Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
EGFR 1956 TYRPHOSTIN AG-1478 CHEMBL7917 inhibitor GuideToPharmacologyInteractions
EGFR 1956 CHEMBL56543 CHEMBL56543 inhibitor GuideToPharmacologyInteractions
EGFR 1956 AC-480 CHEMBL1645462 inhibitor TTD, TdgClinicalTrial, MyCancerGenome, GuideToPharmacologyInteractions, ChemblInteractions, CKB, TALC 21576284
EGFR 1956 BRIGATINIB CHEMBL3545311 inhibitor TALC, CKB, GuideToPharmacologyInteractions, ChemblInteractions, MyCancerGenomeClinicalTrial 27780853, 27836716
EGFR 1956 CUDC-101 CHEMBL598797 inhibitor TALC, TdgClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions 20388807
EGFR 1956 FALNIDAMOL CHEMBL258940 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
EGFR 1956 NERATINIB CHEMBL180022 inhibitor TALC, TdgClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions, TTD 25948633, 20479403, 26206867, 25931286, 17085664, 21325073
EGFR 1956 CHEMBL1951415 CHEMBL1951415 inhibitor GuideToPharmacologyInteractions
EGFR 1956 ALVOCIDIB CHEMBL428690 DrugBank 11752352
EGFR 1956 ZALUTUMUMAB CHEMBL2107861 antagonist, antibody TALC, TdgClinicalTrial, ChemblInteractions, DrugBank
EGFR 1956 INSM-18 CHEMBL3545025 DrugBank
EGFR 1956 DEPATUXIZUMAB CHEMBL3707294 antibody MyCancerGenome, CKB 25895099
EGFR 1956 SB-243213 CHEMBL14460 inhibitor TTD
EGFR 1956 NITROGLYCERIN CHEMBL730 activator TTD
EGFR 1956 NEPIDERMIN CHEMBL2108314 activator TTD
EGFR 1956 PEMETREXED (CHEMBL1201258) CHEMBL1201258 CIViC 24636847
EGFR 1956 CRIZOTINIB CHEMBL601719 CKB, CIViC 21791641, 27595477, 27283993, 27393507
EGFR 1956 ETOPOSIDE CHEMBL44657 CKB 27216155
EGFR 1956 SORAFENIB CHEMBL1336 CKB 24166906, 26743856, 23629727
EGFR 1956 AMG-337 CHEMBL3545212 CKB 26432108
EGFR 1956 DURVALUMAB CHEMBL3301587 CKB 27225694
EGFR 1956 PHA-665752 CHEMBL450786 CKB 26124204, 24165158, 23542356
EGFR 1956 EVEROLIMUS CHEMBL1908360 CKB 23629727
EGFR 1956 DACTOLISIB CHEMBL1879463 CKB 23629727, 24939055
EGFR 1956 CHEMBL1765740 CHEMBL1765740 CKB 28416483
EGFR 1956 SARACATINIB CHEMBL217092 CKB 28416483
EGFR 1956 BOSUTINIB CHEMBL288441 CKB 28416483
EGFR 1956 Pyrotinib CHEMBL3544956 inhibitor ChemblInteractions
EGFR 1956 MDX-447 CHEMBL2109391 ChemblInteractions
EGFR 1956 ERLOTINIB CHEMBL553 antagonist, inhibitor TTD, CGI, DoCM, FDA, DrugBank, GuideToPharmacologyInteractions, OncoKB, MyCancerGenome, PharmGKB, TdgClinicalTrial, TEND, ClearityFoundationClinicalTrial, ClearityFoundationBiomarkers, TALC, CancerCommons, CIViC, CKB 17177598, 16011858, 26619011, 15710947, 16115929, 19671738, 15118073, 19922469, 23102728, 15329413, 15118125, 20479403, 22753918, 25157968, 18199554, 16187797, 24894453, 16204070, 23945392, 2302402, 23242437, 18458038, 16043828, 16707764, 19147750, 17653080, 21233402, 24636847, 21194487, 25923550, 25668228, 24729716, 26720284, 22588155, 21430269, 24893891, 20068085, 23816963, 22215752, 24658966, 21531810, 15728811, 16912157, 18227510, 24623981, 26515464, 25923549, 20033049, 15737014, 16258541, 24065731, 17332364, 22452896, 21783417, 20573926, 19692684, 22452895, 18303429, 19096302, 21670455, 23816960, 19692680, 22285168, 20022809, 23948351, 19455431, 12517254, 11752352, 12820772, 12498017, 12840797, 12814826, 15638953, 14570950, 26051236, 18408761, 24285021, 22190593, 24478319, 22001862, 25589191, 22370314, 26286086, 19625781, 25179728, 23371856, 19536777, 24353160, 21764376, 18676761, 23328547, 1867676, 15897572, 17686547, 26206867, 21949883, 23912954, 25130612, 20808254, 21422421, 23969006, 17285735, 25521405, 21252719, 23566546, 18000506, 23749122, 24457318, 24868098, 17877814, 23470965, 27304188, 16818686, 26768165, 26124334, 15310767, 16282176, 22901364, 21969500, 17085664, 26773740, 23344264, 18981003, 19015641, 28089594, 20942962, 27216155, 19010870, 17349580, 28343545, 25931286, 26106072, 25573954, 25077897, 27825638, 27207775, 27793840, 24470557, 27760111, 27102076, 27913578, 25870087, 26720423, 26324372, 28408243, 27468240, 23917401, 26341921, 24410791, 27694386
EGFR 1956 PANITUMUMAB CHEMBL1201827 agonist, inhibitor, antibody, suppressor ClearityFoundationBiomarkers, GuideToPharmacologyInteractions, DrugBank, FDA, TTD, MyCancerGenome, TALC, TdgClinicalTrial, TEND, CGI, CIViC, CKB, DoCM, ChemblInteractions 12620146, 16012181, 11752352, 20623992, 17355997, 14967460, 18503402, 18343240, 20481659, 11255078, 16857825, 11894013, 24653627, 26888827, 26843189, 22270724, 17664472, 27312529
EGFR 1956 NECITUMUMAB CHEMBL1743047 antagonist, inhibitor, antibody TALC, MyCancerGenome, TdgClinicalTrial, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank 20197484
EGFR 1956 ACALABRUTINIB CHEMBL3707348 inhibitor GuideToPharmacologyInteractions
EGFR 1956 AEE-788 CHEMBL587723 inhibitor MyCancerGenome, CKB, GuideToPharmacologyInteractions, ChemblInteractions, CIViC 19147750, 18227510
EGFR 1956 CHEMBL174426 CHEMBL174426 inhibitor GuideToPharmacologyInteractions
EGFR 1956 CANERTINIB CHEMBL31965 inhibitor MyCancerGenome, GuideToPharmacologyInteractions
EGFR 1956 FELYPRESSIN CHEMBL1908309 inhibitor GuideToPharmacologyInteractions
EGFR 1956 IBRUTINIB CHEMBL1873475 inhibitor GuideToPharmacologyInteractions
EGFR 1956 LAPATINIB CHEMBL554 antagonist, inhibitor DrugBank, TTD, TdgClinicalTrial, GuideToPharmacologyInteractions, CancerCommons, TALC, ClearityFoundationClinicalTrial, TEND, CGI, CIViC, CKB, DoCM 18803986, 14967461, 14737100, 15163842, 14633707, 11752352, 15374980, 20658522, 20110044, 14751502, 16894399, 12214266, 18408761, 23559153, 27595477, 20215545, 18199554, 23917401, 22885469
EGFR 1956 NAQUOTINIB CHEMBL3663929 inhibitor CKB, GuideToPharmacologyInteractions
EGFR 1956 OLMUTINIB CHEMBL3786343 antagonist, inhibitor CKB, GuideToPharmacologyInteractions, CGI, DrugBank
EGFR 1956 OSIMERTINIB CHEMBL3353410 inhibitor MyCancerGenome, OncoKB, CKB, GuideToPharmacologyInteractions, ChemblInteractions, CGI, CIViC, DrugBank, FDA 27198352, 25923549, 24893891, 26720284, 26729184, 27959700, 28202511, 25939061, 25948633, 26206867, 28343545, 26286086, 25870145, 27435396, 27216193, 27393507, 27252416, 24410791, 27102076, 27694386, 28416483, 26522274
EGFR 1956 CHEMBL53753 CHEMBL53753 inhibitor GuideToPharmacologyInteractions
EGFR 1956 PELITINIB CHEMBL607707 inhibitor TALC, MyCancerGenome, CKB, GuideToPharmacologyInteractions, ChemblInteractions 16364494, 16710023
EGFR 1956 CHEMBL306380 CHEMBL306380 inhibitor GuideToPharmacologyInteractions
EGFR 1956 SAPITINIB CHEMBL2408045 inhibitor CKB, GuideToPharmacologyInteractions, ChemblInteractions 20145185, 24886365
EGFR 1956 POTASSIUM CHLORIDE CHEMBL1200731 GuideToPharmacologyInteractions
EGFR 1956 DULIGOTUZUMAB CHEMBL3137345 antibody TALC, MyCancerGenome
EGFR 1956 Futuximab CHEMBL2109388 antibody MyCancerGenome, TdgClinicalTrial, CKB, CIViC 26888827, 25962717, 24204198, 24130052
EGFR 1956 GELDANAMYCIN CHEMBL278315 PharmGKB
EGFR 1956 LIDOCAINE CHEMBL79 TdgClinicalTrial
EGFR 1956 S-222611 CHEMBL3545200 inhibitor CKB, ChemblInteractions, TTD 25434923, 24837299
EGFR 1956 TRAMETINIB CHEMBL2103875 CKB 26036643, 26582713, 27312529, 28783719
EGFR 1956 CAPMATINIB CHEMBL3188267 CKB 28783719
EGFR 1956 DECITABINE CHEMBL1201129 CKB 24874286
EGFR 1956 JNJ-42756493 CHEMBL3545376 CKB 28341788
EGFR 1956 SELUMETINIB CHEMBL1614701 CKB 27312529, 27287717, 25870145, 28416483, 24939055
EGFR 1956 ENCORAFENIB CHEMBL3301612 CKB 27312529
EGFR 1956 SUNITINIB CHEMBL535 CKB 27149458
EGFR 1956 DASATINIB CHEMBL1421 CKB 28416483
EGFR 1956 PIMASERTIB CHEMBL2107832 CKB 23629727
EGFR 1956 REGORAFENIB CHEMBL1946170 CKB 23629727
EGFR 1956 AFATINIB DIMALEATE CHEMBL2105712 inhibitor ChemblInteractions
EGFR 1956 HM-61713 CHEMBL3545430 inhibitor ChemblInteractions
EGFR 1956 MP-412 CHEMBL3545002 inhibitor ChemblInteractions
EGFR 1956 mAb-425 CHEMBL2109390 inhibitor ChemblInteractions
EGFR 1956 RG-7160 CHEMBL2109393 antagonist ChemblInteractions
EGFR 1956 Puquitinib CHEMBL3545088 inhibitor ChemblInteractions
EGFR 1956 Theliatinib CHEMBL3545180 inhibitor ChemblInteractions
EGFR 1956 JNJ-26483327 CHEMBL3545133 inhibitor ChemblInteractions
EGFR 1956 TRASTUZUMAB CHEMBL1201585 TEND, DrugBank 11752352
EGFR 1956 DACOMITINIB CHEMBL2110732 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions, CIViC, CancerCommons, MyCancerGenomeClinicalTrial 26768165, 21430269, 24857124, 28363995, 27913578, 26206867, 26561558, 25939761, 25456362, 18089823, 21764376
EGFR 1956 ICOTINIB CHEMBL2087361 antagonist, inhibitor CKB, GuideToPharmacologyInteractions, DrugBank, TALC, MyCancerGenomeClinicalTrial, MyCancerGenome 23372346, 24438614, 25261231, 2394835, 27468240, 24533047
EGFR 1956 PKI-166 CHEMBL1963502 inhibitor GuideToPharmacologyInteractions, ChemblInteractions
EGFR 1956 Poziotinib CHEMBL3545154 inhibitor CKB, GuideToPharmacologyInteractions, ChemblInteractions, MyCancerGenomeClinicalTrial
EGFR 1956 CHEMBL1081312 CHEMBL1081312 inhibitor GuideToPharmacologyInteractions
EGFR 1956 CHEMBL1229592 CHEMBL1229592 inhibitor CKB, GuideToPharmacologyInteractions 26036643, 25948633, 25964297, 25870145
EGFR 1956 PROCATEROL CHEMBL160519 GuideToPharmacologyInteractions
EGFR 1956 CAPREOMYCINE CHEMBL2221250 GuideToPharmacologyInteractions
EGFR 1956 RINDOPEPIMUT CHEMBL2107863 TdgClinicalTrial, CIViC, DrugBank 25586468
EGFR 1956 CHEMBL2141478 CHEMBL2141478 inhibitor TALC
EGFR 1956 CABOZANTINIB CHEMBL2105717 CKB 27825638, 27694386
EGFR 1956 IMATINIB CHEMBL941 CKB 22323597
EGFR 1956 VEMURAFENIB CHEMBL1229517 CKB 27312529
EGFR 1956 NIVOLUMAB CHEMBL2108738 CKB 28407039, 27225694
EGFR 1956 PONATINIB CHEMBL1171837 CKB 22238366
EGFR 1956 PEMBROLIZUMAB CHEMBL3137343 CKB 27225694
EGFR 1956 MGCD-265 CHEMBL254760 CKB
EGFR 1956 BUPARLISIB CHEMBL2017974 CKB 28416483
EGFR 1956 Epitinib CHEMBL3545121 inhibitor CKB, ChemblInteractions
EGFR 1956 OSIMERTINIB MESYLATE CHEMBL3545063 inhibitor ChemblInteractions
EGFR 1956 CEP-32496 CHEMBL2029988 inhibitor ChemblInteractions
EGFR 1956 CANERTINIB DIHYDROCHLORIDE CHEMBL545315 inhibitor ChemblInteractions
EGFR 1956 CETUXIMAB CHEMBL1201577 antagonist, inhibitor, antibody FDA, TEND, ChemblInteractions, DrugBank, GuideToPharmacologyInteractions, OncoKB, MyCancerGenome, TTD, TALC, ClearityFoundationBiomarkers, CancerCommons, TdgClinicalTrial, CGI, CIViC, CKB, DoCM 10601294, 11752352, 11431346, 10628369, 11408594, 10480573, 22001862, 22270724, 26059438, 25623215, 26888827, 24894453, 24653627, 18794099, 18003960, 24934779, 26843189, 27216155, 27312529, 24141978, 27207775, 27251290, 25948633, 27149458, 26341921, 24813888, 24063894, 27102076, 23578570, 16011858, 26619011, 15710947, 16115929, 19671738, 15118073, 19922469, 23102728, 15329413, 15118125, 20479403, 22753918, 25157968, 18199554, 16187797, 16204070, 23945392, 2302402, 23242437, 18458038, 16043828, 18089823, 16707764, 19147750, 17653080, 21233402, 24636847, 21194487, 25923550, 25668228, 24729716, 26720284, 22588155, 21430269, 24893891, 20068085, 23816963, 22215752, 24658966, 21531810, 15728811, 16912157, 18227510, 24623981, 26515464, 25923549, 20033049, 15737014, 16258541, 24065731, 17332364, 22452896, 21783417, 20573926, 19692684, 22452895, 18303429, 19096302, 21670455, 23816960, 19692680, 22285168, 20022809, 23948351, 19455431
EGFR 1956 GEFITINIB CHEMBL939 antagonist, inhibitor GuideToPharmacologyInteractions, PharmGKB, TdgClinicalTrial, TEND, DrugBank, OncoKB, MyCancerGenome, TTD, TALC, CancerCommons, ClearityFoundationBiomarkers, MyCancerGenomeClinicalTrial, CGI, CIViC, CKB, DoCM, ChemblInteractions, FDA 11752352, 11566608, 11673690, 10815932, 11522647, 11585753, 21531810, 15638953, 14570950, 15118073, 26051236, 21670455, 18408761, 16011858, 16187797, 24285021, 20573926, 22190593, 24478319, 23816963, 22452895, 25589191, 23816960, 22285168, 20022809, 19692680, 22370314, 26286086, 19625781, 25179728, 15737014, 23371856, 24065731, 19536777, 24353160, 21764376, 18676761, 24893891, 23328547, 1867676, 15897572, 17686547, 26206867, 21949883, 23912954, 25130612, 20808254, 21422421, 23969006, 21252719, 28537764, 25070024, 26980463, 23566546, 18000506, 23749122, 15710947, 21274259, 22261807, 24457318, 15118125, 18509184, 19147750, 15728811, 18227510, 23470965, 27304188, 16730237, 16818686, 26124334, 16707605, 16282176, 12748244, 22901364, 15329413, 20038723, 17085664, 23344264, 18981003, 20942962, 28089594, 17349580, 26561558, 25931286, 24874286, 25573954, 23980091, 27196752, 22323597, 27793840, 25948633, 25964297, 27312529, 22997455, 27468240, 26124204, 27612490, 24165158, 23542356, 24736073, 26936917, 22263058, 25870145, 24410791, 24533047, 17463250, 22789825
EGFR 1956 AFATINIB CHEMBL1173655 inhibitor GuideToPharmacologyInteractions, MyCancerGenome, MyCancerGenomeClinicalTrial, CGI, DrugBank, FDA, OncoKB, CancerCommons, TdgClinicalTrial, TTD, TALC, CIViC, CKB, DoCM 21531810, 15638953, 14570950, 15118073, 26051236, 21670455, 18408761, 16011858, 16187797, 24285021, 20573926, 22190593, 24478319, 23816963, 22452895, 25589191, 23816960, 22285168, 20022809, 19692680, 22370314, 26286086, 19625781, 25179728, 15737014, 23371856, 24065731, 19536777, 24353160, 21764376, 18676761, 24893891, 23328547, 1867676, 15897572, 17686547, 26206867, 21949883, 23912954, 25130612, 20808254, 21422421, 23969006, 17285735, 25521405, 21252719, 23566546, 18000506, 23749122, 15710947, 24439929, 23982599, 27304188, 24035188, 27083334, 24790411, 26354527, 28363995, 25948633, 27913578, 17349580, 23344264, 27044931, 25559287, 27207775, 25964297, 28169392, 25589492, 21617858, 26862733, 28145866, 26341921, 25077897, 24813888, 25870145, 23991291, 27102076, 27694386, 26619011, 16115929, 19671738, 19922469, 23102728, 15329413, 15118125, 20479403, 22753918, 25157968, 18199554, 24894453, 16204070, 23945392, 2302402, 23242437, 18458038, 16043828, 16707764, 19147750, 17653080, 21233402, 24636847, 21194487, 25923550, 25668228, 24729716, 26720284, 22588155, 21430269, 20068085, 22215752, 24658966, 15728811, 16912157, 18227510, 24623981, 26515464, 25923549, 20033049, 16258541, 17332364, 22452896, 21783417, 19692684, 18303429, 19096302, 23948351, 19455431
EGFR 1956 BGB-283 CHEMBL3545246 inhibitor CKB, GuideToPharmacologyInteractions 26208524
EGFR 1956 DOVITINIB CHEMBL522892 inhibitor GuideToPharmacologyInteractions
EGFR 1956 ORANTINIB CHEMBL274654 inhibitor GuideToPharmacologyInteractions
EGFR 1956 ROCILETINIB CHEMBL3545308 inhibitor TALC, MyCancerGenome, CKB, GuideToPharmacologyInteractions, ChemblInteractions, CGI, CIViC 25923550, 24065731, 28202511, 25948633, 26206867, 25939061, 27283993, 27252416, 27435396
EGFR 1956 MATUZUMAB CHEMBL2108038 inhibitor ChemblInteractions, DrugBank
EGFR 1956 CHEMBL285063 CHEMBL285063 DrugBank 10592235
EGFR 1956 EGF816 CHEMBL3545234 inhibitor OncoKB, CKB, ChemblInteractions 26825170
EGFR 1956 MOMELOTINIB CHEMBL1078178 inhibitor TALC
EGFR 1956 ERLOTINIB HYDROCHLORIDE CHEMBL1079742 inhibitor ChemblInteractions, MyCancerGenomeClinicalTrial
EGFR 1956 LAPATINIB DITOSYLATE CHEMBL1201179 inhibitor ChemblInteractions, MyCancerGenomeClinicalTrial, TTD
EGFR 1956 AZD-4769 CHEMBL422872 inhibitor ChemblInteractions, TTD
EGFR 1956 MUBRITINIB CHEMBL1614707 inhibitor TTD
EGFR 1956 SIROLIMUS CHEMBL413 CKB, CGI, CIViC, DoCM 24813888, 25157968, 24934779, 18089823
EGFR 1956 PACLITAXEL CHEMBL428647 CKB, CIViC 22139083, 24886365
EGFR 1956 MK-2206 CHEMBL1079175 CKB 26106072
EGFR 1956 DABRAFENIB CHEMBL2028663 CKB 27312529
EGFR 1956 ATEZOLIZUMAB CHEMBL3707227 CKB 27225694
EGFR 1956 AMLEXANOX CHEMBL1096 CKB 27287717
EGFR 1956 GEDATOLISIB CHEMBL592445 CKB 21325073, 16731747, 19238632
EGFR 1956 Savolitinib CHEMBL3545336 CKB 27694386
EGFR 1956 Allitinib CHEMBL3545244 inhibitor ChemblInteractions
EGFR 1956 PD-0166285 (CHEMBL3545196) CHEMBL3545196 inhibitor ChemblInteractions
EGFR 1956 VARLITINIB CHEMBL2103842 inhibitor ChemblInteractions
EGFR 1956 DACOMITINIB HYDRATE CHEMBL2105719 inhibitor ChemblInteractions
EGFR 1956 Simotinib CHEMBL3545235 inhibitor ChemblInteractions
EGFR 1956 CHEMBL387187 CHEMBL387187 inhibitor GuideToPharmacologyInteractions, CIViC 20826716, 22056021, 26439803, 16282176
EGFR 1956 ALCOHOL CHEMBL545 NCI 10092515
EGFR 1956 LINSITINIB CHEMBL1091644 CKB 26561558
EGFR 1956 PF-00477736 CHEMBL3545137 CKB 26140595
EGFR 1956 BMS-690514 CHEMBL3545396 inhibitor TALC, MyCancerGenome, CKB, GuideToPharmacologyInteractions, ChemblInteractions 23490650
EGFR 1956 VANDETANIB CHEMBL24828 inhibitor TALC, ClearityFoundationBiomarkers, MyCancerGenome, TdgClinicalTrial, ClearityFoundationClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions, DrugBank, MyCancerGenomeClinicalTrial, TTD 25910950
EGFR 1956 BMS-754807 CHEMBL575448 CKB 26561558
EGFR 1956 DEPATUXIZUMAB MAFODOTIN CHEMBL3707277 CKB 26846818
EGFR 1956 TEMOZOLOMIDE CHEMBL810 CKB 26846818, 25910950
EGFR 1956 TEMSIROLIMUS CHEMBL1201182 CKB 24470557
EGFR 1956 IRINOTECAN CHEMBL481 CKB 23209031, 25185971
EGFR 1956 ERISMODEGIB CHEMBL2105737 CKB 26124204
EGFR 1956 NIMOTUZUMAB CHEMBL2108359 antibody TALC, MyCancerGenome, TdgClinicalTrial, CKB, CGI 25185971
EGFR 1956 IMGATUZUMAB CHEMBL2109389 antibody TALC, MyCancerGenome, CKB 23209031
EGFR 1956 TAK-285 CHEMBL1614725 inhibitor CKB, ChemblInteractions 23983820
EGFR 1956 GOLVATINIB CHEMBL3039525 CKB 22789825
EGFR 1956 TESEVATINIB CHEMBL3544983 inhibitor TALC, MyCancerGenome, TdgClinicalTrial, CKB, GuideToPharmacologyInteractions, ChemblInteractions 22722787
EGFR 1956 IGN-311 CHEMBL2109501 DrugBank 16963623
EGFR 1956 CARBOPLATIN CHEMBL1351 CIViC 22139083
EGFR 1956 AZD-4547 CHEMBL3184679 CKB 26936917
EGFR 1956 GANETESPIB CHEMBL2103879 CKB 25077897
EGFR 1956 CHEMBL458997 CHEMBL458997 CKB 26090892
EGFR 1956 NVP-AUY922 CHEMBL252164 CKB 25870087
EGFR 1956 BEVACIZUMAB CHEMBL1201583 CKB 28408243
EGFR 1956 CHEMBL1231206 CHEMBL1231206 CKB 26140595

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
EGFR rs121434568 G erlotinib efficacy yes as compared to exon 19 deletion mutations in EGFR regardless of the type of tyrosine kinase inhibitor treatment (first line or mixed). Patients who carried exon 19 deletion mutations in EGFR responded better to TKI treatment as compared to patients with the rs121434568 T>G mutation in EGFR. Allele G is associated with decreased response to erlotinib or gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to allele T. 26490356 1446908230
EGFR rs121434568 GT + TT erlotinib efficacy yes response = progression free survival. Noted: some confusion about the wording of sections of this article vs. some of the tables. Numbers from the Abstract were used. Report was in terms of presence/absence of L858R mutation, and was assessed from baseline SERUM DNA. Genotypes GT + TT are associated with decreased response to erlotinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. 19692684 827921493
EGFR rs2227983 A cetuximab efficacy no Allele A is not associated with response to cetuximab in people with Colorectal Neoplasms as compared to allele G. 16788380 637880031
EGFR rs121434568 GT gefitinib efficacy not stated This variant was present in 2 out of 8 tumor samples from responsive patients and not in normal matched tissue. Genotype GT is associated with increased response to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT. 15118073 827926134
EGFR rs2293347 CC fluorouracil efficacy yes Response was defined as complete or partial response according to response evaluation criteria in solid tumors (RECIST); non-response was defined as no change or progressive disease. A greater percentage of those with the CC genotype were non-responders. Please note alleles have been complemented to the plus chromosomal strand. Genotype CC is associated with decreased response to fluorouracil in people with Stomach Neoplasms as compared to genotypes CT + TT. 23816762 1184510370
EGFR rs712829 GG cetuximab efficacy no No significant difference in disease control rate was seen between the two genotype groups. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease). Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes GT + TT. 23959273 1184510725
EGFR rs2227983 GG cetuximab efficacy no No significant difference in disease control rate was seen between the genotype groups. Using the Response Evaluation Criteria in Solid Tumors (RECIST), disease control rate was the percentage of patients with complete response, partial response or stable disease (as opposed to patients with progressive disease). Genotype GG is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to genotypes AA + AG. 23959273 1184510737
EGFR rs11568315 19 cetuximab efficacy no Comparisons in response rate (response = complete or partial response), disease control rate (control = complete or partial response or stable disease), progression-free survival and overall survival were between patients homozygous for a "short" variant (that is, <20 CA repeats) and patients who carried one or more "long" variants (that is >= 20 CA repeats). However, no significant differences were seen when considering any of these phenotypes. Additionally, no significant differences were seen when considering cutoff values of 17 or sum of 35 repeats. Allele 19 is not associated with response to cetuximab and irinotecan in people with Colorectal Neoplasms as compared to allele 20. 24513691 1184747790
EGFR rs121434568 G afatinib efficacy no as first line agents and as compared to chemotherapy. These results are for a meta-analysis of clinical trials (LUXLUNG6, LUXLUNG3). A random effects model was used to compile the results since there was heterogeneity across the trials. Progression free and overall survival (PFS, OS) were the measures of response. As compared to standard chemotherapy, patients with this SNP had increased PFS, but not OS when taking afatinib. Overall, however, a different EGFR mutation, "exon 19 del", had a greater improvement in response to tyrosine kinase inhibitors (TKIs) as compared to chemotherapy than the rs121434568 T>G mutation [(PFS "exon 19 del"/rs121434568 T>G HR 0.58 (95% CI 0.45-0.75); p-value= 0.001) and OS "exon 19 del"/rs121434568 T>G HR 0.75 (95% CI 0.58-0.94)' p-value=0.018)]. Allele G is not associated with response to afatinib in people with Carcinoma, Non-Small-Cell Lung. 26490356 1446908196
EGFR rs2227983 A cetuximab efficacy no Meta-analysis with 6 studies. This association was not significant after multiple testing correction. This variant was listed as rs11543848 in the original article. The authors did not provide the exact number of patients but stated that "the median number of patients per analysis was 110 (range 50 - 740)". Most definitions of response were variations of the RECIST criteria. Allele A is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele G. 27897268 1449165367
EGFR rs712829 T cetuximab efficacy no Meta-analysis with 3 studies. The authors did not provide the exact number of patients but stated that "the median number of patients per analysis was 110 (range 50 - 740)". Most definitions of response were variations of the RECIST criteria. Allele T is not associated with response to cetuximab or panitumumab in people with Colorectal Neoplasms as compared to allele G. 27897268 1449165359
EGFR rs121434568 G gefitinib efficacy yes as first line agents and as compared to chemotherapy. These results are for a meta-analysis of clinical trials (IPASS, WTJOG3405, NEJ002). A random effects model was used to compile the results since there was heterogeneity across the trials. Progression free and overall survival (PFS, OS) were the measures of response. As compared to standard chemotherapy, patients with this SNP had increased PFS, but not OS when taking gefitinib. Overall, however, a different EGFR mutation, "exon 19 del", had a greater improvement in response to tyrosine kinase inhibitors (TKIs) as compared to chemotherapy than the rs121434568 T>G mutation [(PFS "exon 19 del"/rs121434568 T>G HR 0.58 (95% CI 0.45-0.75); p-value= 0.001) and OS "exon 19 del"/rs121434568 T>G HR 0.75 (95% CI 0.58-0.94)' p-value=0.018)]. Allele G is associated with response to gefitinib in people with Carcinoma, Non-Small-Cell Lung. 26490356 1446908159
EGFR rs121434568 G erlotinib efficacy yes as first line agents and as compared to chemotherapy. These results are for a meta-analysis of clinical trials (OPTIMAL, EURTAC, ENSURE). A random effects model was used to compile the results since there was heterogeneity across the trials. Progression free and overall survival (PFS, OS) were the measures of response. As compared to standard chemotherapy, patients with this SNP had increased PFS, but not OS when taking erlotinib. Overall, however, a different EGFR mutation, "exon 19 del", had a greater improvement in response to tyrosine kinase inhibitors (TKIs) as compared to chemotherapy than the rs121434568 T>G mutation [(PFS "exon 19 del"/rs121434568 T>G HR 0.58 (95% CI 0.45-0.75); p-value= 0.001) and OS "exon 19 del"/rs121434568 T>G HR 0.75 (95% CI 0.58-0.94)' p-value=0.018)]. Allele G is associated with response to erlotinib in people with Carcinoma, Non-Small-Cell Lung. 26490356 1446908186